The Zhitong Finance App learned that Changfeng Pharmaceutical (02652) rose by more than 23%. As of press release, it had risen 12.03% to HK$17.07, with a turnover of HK$74.1826 million.
According to the news, Changfeng Pharmaceutical announced that ICF001, a candidate drug for long-term inhalation dry powder developed independently by the Group, has obtained implied permission from the State Drug Administration to conduct clinical trials on interstitial lung disease (i.e. idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)). So far, ICF001 has achieved full coverage of the four major indications of PAH, PH-ILD, IPF, and PPF. The product positioning is highly aligned with the development direction of the world's latest generation long-term inhalation prodrug, and has established a solid regulatory foundation for the company's subsequent global multi-center clinical layout, registration strategy planning, and overseas strategic cooperation.
ICF001 is a pulmonary prodrug with significant logical advantages in the design of long-lasting inhalation prodrug. Two new clinical studies with new indications will greatly enhance clinical value. In China, PAH treatment has moved towards multi-mechanism combination, but the supply of inhaled formulations and long-acting prodrug products is still limited, and there are still unmet clinical needs in the PH-ILD, IPF, and PPF fields. Furthermore, the company plans to conduct phase I clinical trials in China, and also plans to simultaneously launch phase I clinical studies at home and abroad, and conduct clinical trials overseas on the premise of obtaining the required approval from relevant overseas regulators.